BCL2 and neoplasm: Tumor cells regained sensitivity to ABT-737 or Venetoclax as Mcl-1 gene was knocked out in leukemia cells, which suggested Mcl-1 was the primary reason of resistance to anti-Bcl-2 compounds (Nguyen et al., 2007; Punnoose et al., 2016).